HLA Class I alleles associated with HCV polymorphisms and response to antiviral therapy in HCV genotype 1-infected patients

Aims: The adaptive immune response against hepatitis C virus (HCV) is significantly shaped by the host's composition of HLA alleles. Thus, the HLA phenotype is a critical determinant of viral evolution during adaptive immune pressure. Potential associations of HLA class I alleles with polymorphisms of HCV immune escape variants are largely unknown. Methods: Direct sequence analysis of the genes encoding the HCV proteins E2, NS3 and NS5B in a cohort of 159 patients with chronic HCV genotype 1 infection who were treated with pegylated interferon-alfa 2b and ribavirin in a prospective controlled trial for 48 weeks was exhibited. HLA class I genotyping was performed by strand-specific reverse hybridization with the INNO-LiPA line probe assays for HLA-A and HLA-B and by strand-specific PCR-SSP. We analyzed each amino acid position of HCV proteins using an extension of Fisher's exact test for associations with HLA alleles. In addition, associations of specific HLA alleles with inflammatory activity, liver fibrosis, HCV RNA viral load and virologic treatment outcome were investigated. Results: Separate analyses of HCV subtype 1a and 1b isolates revealed substantially different patterns of HLA-restricted polymorphisms between subtypes. Only one polymorphism within NS5B (V2758x) was significantly associated with HLA B*15 in HCV genotype 1b infected patients (adjusted p=0,048). However, a number of HLA class I-restricted polymorphisms within novel putative HCV CD8+ T cell epitopes (genotype 1a: HLA-A*11 GTRTIASPK1086-1094 [NS3], HLA-B*07 WPAPQGARSL1111-1120 [NS3]; genotype 1b: HLA-A*24 HYAPRPCGI488-496 [E2], HLA-B*44 GENETDVLL530-538 [E2], HLA-B*15 RVFTEAMTRY2757-2766 [NS5B]) were observed with high predicted epitope binding scores assessed by the web-based software SYFPEITHI (>21). Most of the identified putative epitopes were overlapping with already otherwise published epitopes, indicating a high immunogenicity of the accordant HCV protein region. In addition, certain HLA class I alleles were associated with inflammatory activity, stage of liver fibrosis, and sustained virologic response to antiviral therapy. Conclusions: HLA class I restricted HCV sequence polymorphisms are rare. HCV polymorphisms identified within putative HCV CD8+ T cell epitopes in the present study differ in their genomic distribution between genotype 1a and 1b isolates, implying divergent adaptation to the host's immune pressure on the HCV subtype level.

Establishment of animal models to analyze the kinetics and distribution of human tumor antigen-specific CD8⁺ T cells.

Many patients develop tumor antigen-specific T cell responses detectable in peripheral blood mononuclear cells (PBMCs) following cancer vaccine. However, measurable tumor regression is observed in a limited number of patients receiving cancer vaccines. There is a need to re-evaluate systemically the immune responses induced by cancer vaccines. Here, we established animal models targeting two human cancer/testis antigens, NY-ESO-1 and MAGE-A4. Cytotoxic T lymphocyte (CTL) epitopes of these antigens were investigated by immunizing BALB/c mice with plasmids encoding the entire sequences of NY-ESO-1 or MAGE-A4. CD8(+) T cells specific for NY-ESO-1 or MAGE-A4 were able to be detected by ELISPOT assays using antigen presenting cells pulsed with overlapping peptides covering the whole protein, indicating the high immunogenicity of these antigens in mice. Truncation of these peptides revealed that NY-ESO-1-specific CD8(+) T cells recognized D(d)-restricted 8mer peptides, NY-ESO-181-88. MAGE-A4-specific CD8(+) T cells recognized D(d)-restricted 9mer peptides, MAGE-A4265-273. MHC/peptide tetramers allowed us to analyze the kinetics and distribution of the antigen-specific immune responses, and we found that stronger antigen-specific CD8(+) T cell responses were required for more effective anti-tumor activity. Taken together, these animal models are valuable for evaluation of immune responses and optimization of the efficacy of cancer vaccines.

Automated Segmentation of Cerebral Vasculature with Aneurysms in 3DRA and TOF-MRA using Geodesic Active Regions: an Evaluation Study

Purpose: To evaluate the suitability of an improved version of an automatic segmentation method based on geodesic active regions (GAR) for segmenting cerebral vasculature with aneurysms from 3D X-ray reconstruc-tion angiography (3DRA) and time of °ight magnetic resonance angiography (TOF-MRA) images available in the clinical routine.Methods: Three aspects of the GAR method have been improved: execution time, robustness to variability in imaging protocols and robustness to variability in image spatial resolutions. The improved GAR was retrospectively evaluated on images from patients containing intracranial aneurysms in the area of the Circle of Willis and imaged with two modalities: 3DRA and TOF-MRA. Images were obtained from two clinical centers, each using di®erent imaging equipment. Evaluation included qualitative and quantitative analyses ofthe segmentation results on 20 images from 10 patients. The gold standard was built from 660 cross-sections (33 per image) of vessels and aneurysms, manually measured by interventional neuroradiologists. GAR has also been compared to an interactive segmentation method: iso-intensity surface extraction (ISE). In addition, since patients had been imaged with the two modalities, we performed an inter-modality agreement analysis with respect to both the manual measurements and each of the two segmentation methods. Results: Both GAR and ISE di®ered from the gold standard within acceptable limits compared to the imaging resolution. GAR (ISE, respectively) had an average accuracy of 0.20 (0.24) mm for 3DRA and 0.27 (0.30) mm for TOF-MRA, and had a repeatability of 0.05 (0.20) mm. Compared to ISE, GAR had a lower qualitative error in the vessel region and a lower quantitative error in the aneurysm region. The repeatabilityof GAR was superior to manual measurements and ISE. The inter-modality agreement was similar between GAR and the manual measurements. Conclusions: The improved GAR method outperformed ISE qualitatively as well as quantitatively and is suitable for segmenting 3DRA and TOF-MRA images from clinical routine.

A Genetic Validation Study Reveals a Role of Vitamin D Metabolism in the Response to Interferon-Alfa-Based Therapy of Chronic Hepatitis C.

BACKGROUND: To perform a comprehensive study on the relationship between vitamin D metabolism and the response to interferon-α-based therapy of chronic hepatitis C. METHODOLOGY/PRINCIPAL FINDINGS: Associations between a functionally relevant polymorphism in the gene encoding the vitamin D 1α-hydroxylase (CYP27B1-1260 rs10877012) and the response to treatment with pegylated interferon-α (PEG-IFN-α) and ribavirin were determined in 701 patients with chronic hepatitis C. In addition, associations between serum concentrations of 25-hydroxyvitamin D(3) (25[OH]D(3)) and treatment outcome were analysed. CYP27B1-1260 rs10877012 was found to be an independent predictor of sustained virologic response (SVR) in patients with poor-response IL28B genotypes (15% difference in SVR for rs10877012 genotype AA vs. CC, p = 0.02, OR = 1.52, 95% CI = 1.061-2.188), but not in patients with favourable IL28B genotype. Patients with chronic hepatitis C showed a high prevalence of vitamin D insufficiency (25[OH]D(3)<20 ng/mL) during all seasons, but 25(OH)D(3) serum levels were not associated with treatment outcome. CONCLUSIONS/SIGNIFICANCE: Our study suggests a role of bioactive vitamin D (1,25[OH](2)D(3), calcitriol) in the response to treatment of chronic hepatitis C. However, serum concentration of the calcitriol precursor 25(OH)D(3) is not a suitable predictor of treatment outcome.

ATS3-testausjärjestelmän evaluointi

Työ tehtiin Nokia Technology Platforms S60 Mobile Runtime-yksikölle. Työn tavoitteena oli evaluoida ATS3-testausjärjestelmä. ATS3-järjestelmällä voidaan automatisoida ohjelmistotestausta. Evaluoinnilla pyrittiin selvittämään voidaanko tuotekehitysvaiheessa oleva järjestelmä ottaa jo käyttöön vai vaatiiko se vielä lisäkehitystä. Työssä kerrotaan aluksi yleisesti ohjelmistotestauksesta. Siinä käydään läpi myös testausprosessin vaiheet sekä kerrotaan lyhyesti avuksi kehitetyistä työkaluista. Työssä kerrotaan myös ATS3-järjestelmän edeltäjien ominaisuuksista, sekä miten ne eroavat tarkastelun kohteena olevasta järjestelmästä. Varsinainen evaluointi alkoi tutustumalla ja asentamalla järjestelmä. Tämän jälkeen suoritettiin samat testit sekä ATS2.x-järjestelmässä että ATS3-järjestelmäss. Testauksen jälkeen analysoitiin testitulosten yhdenmukaisuuden perusteella, voidaanko siirtyä käyttömään ATS3-järjestelmää. Testitulokset olivat käytännässä yhdenmukaiset suoritettaessa testejä matkapuhelimessa, mutta emulaattoritestaus täytyi jättää väliin. Lukuisista yrityksistä sekä järjestelmän kehittäjän avusta huolimatta testejä ei onnistuttu suorittamaan ATS3-järjestelmän emulaattoriympäristössä. Näin ollen päädyttiin tulokseen, ettei järjestelmää voida ottaa vielä käytöön emulaattoritestauksessa, vaan se vaatii lisätutkimusta sekä perehtymistä järjestelmään.

Rutiinimenetelmillä ja Vitek2-laitteella saatujen tulosten vertailu bakteerien identifikaatio- ja antibioottiherkkyystutkimuksissa

Nykyään bakteerien identifikaatio- ja antibioottiherkkyysmääritykset tehdään kliinisen mikrobiologian laboratorioissa suurimmaksi osaksi manuaalisesti. Näytemäärät ovat lisääntyneet bakteriologian laboratorioissa, ja siksi diagnostiikan automatisointi on tullut tarpeelliseksi. BioMerieux on kehittänyt Vitek2-laitteen, jolla voidaan tehdä bakteerien ja sienien identifikaatio ja antibiootti-herkkyys-määrityksiä. Opinnäytetyön tarkoituksena oli verrata rutiinimenetelmien ja Vitek2laitteen identifikaatio- ja antibioottiherkkyystuloksia. Yksittäisiä vertailtavia kohteita olivat testireaktiot, ESBL (Extended Spectrum Beta-Lactamase) -ominaisuus ja määrityksiin kulunut aika. HUSLABin toimeksiannosta Vitek2-laitteella tutkittiin ESBL-kantoja sekä rutiinimenetelmillä vaikeasti tunnistettavia nonfermenta-tiivisia sauvabakteereja ja kasvuolosuhteiltaan vaativia bakteereja. Laitetta varten on kehitetty uusia testikortteja, jotka tunnistavat näitä bakteerik antoja. Aikaisemmat identifikaatio-, reaktio- ja antibioottiherkkyystulokset kerättiin HUSLABin potilastieto-järjestelmästä. Niitä verrattiin Vitek2-laitteesta saatuihin tuloksiin. Määritysten kestoa Vitek2-laitteella verrattiin aikaisempiin tutkimuksiin. Tutkimuksessa käytettiin yhteensä 183 bakteerinäytettä, joista 76 oli ESBL-kantoja, 40 nonfermentatiivisia sauvabakteereja, 41 kasvuolosuhteiltaan vaativia bakteereja sekä 26 uusia potilasnäytelöydöksiä. Vitek2 antoi 99 prosentille kaikista tutkituista ESB--kannoista saman identifikaation kuin rutiini-menetelmät. Uusista potilasnäytelöydöksistä Vitek2 tunnisti 96 Nonfermentatiivisista sauva-baktee-reista ja kasvuolosuhteiltaan vaativista bakteereista Vitek2 tunnisti noin 70 amalla tavalla kuin rutiinimenetelmät. Vitek2-laitteen antamat identifikaatioreaktiotulokset vastasivat paremmin Api20E-testin (94 kuin Api20NE-testin (70 reaktiotuloksia. Noin 80 aikista antibiootti-herkkyys-tuloksista vastasi perinteisillä menet elmillä saatuja tuloksia. Vitek2-laitteella saadut antibiootti-herkkyystulokset olivat yleensä rutiinimenetelmiä herkempiä. Vitek2-laitteella saadut ESBL-tulokset vastasivat rutiinimenetelmillä saatuja tuloksia noin 90-prosenttisesti. Verrattuna aikaisempiin tutkimuksiin Vitek2-laitteen suorittamat määritykset olivat rutiinimenetelmiä paljon nopeampia. Tulosten perusteella voidaan sanoa, että Vitek2-laite on käyttökelpoinen bakteriologian laboratoriossa identifikaatio- ja antibioottiherkkyystutkimuksissa. Nonfermentatiivisia sauvabakteereja ja kasvuolo-suhteiltaan vaativia bakteereja voisi kuitenkin tutkia enemmän.

Cartilage thickness at the posterior medial femoral condyle is increased in femorotibial knee osteoarthritis: a cross-sectional CT arthrography study (Part 2).

OBJECTIVE: To evaluate the thickness of cartilage at the posterior aspect of the medial and lateral condyle in Osteoarthritis (OA) knees compared to non-OA knees using computed tomography arthrography (CTA). DESIGN: 535 consecutive knee CTAs (mean patient age = 48.7 ± 16.0; 286 males), were retrospectively analyzed. Knees were radiographically classified into OA or non-OA knees according to a modified Kellgren/Lawrence (K/L) grading scheme. Cartilage thickness at the posterior aspect of the medial and lateral femoral condyles was measured on sagittal reformations, and compared between matched OA and non-OA knees in the whole sample population and in subgroups defined by gender and age. RESULTS: The cartilage of the posterior aspect of medial condyle was statistically significantly thicker in OA knees (2.43 mm (95% confidence interval (CI) = 2.36, 2.51)) compared to non-OA knees (2.13 mm (95%CI = 2.02, 2.17)) in the entire sample population (P < 0.001), as well as for all subgroups of patients over 40 years old (all P ≤ 0.01), except for females above 60 years old (P = 0.07). Increase in cartilage thickness at the posterior aspect of the medial condyle was associated with increasing K/L grade in the entire sample population, as well as for males and females separately (regression coefficient = 0.10-0.12, all P < 0.001). For the lateral condyle, there was no statistically significant association between cartilage thickness and OA (either presence of OA or K/L grade). CONCLUSIONS: Cartilage thickness at the non-weight-bearing posterior aspect of the medial condyle, but not of the lateral condyle, was increased in OA knees compared to non-OA knees. Furthermore, cartilage thickness at the posterior aspect of the medial condyle increased with increasing K/L grade.